Statement: Intervention of Cohort B is described as Afatinib 50 mg, taken orally, bi-weekly.
Primary_evidence: INTERVENTION 1:    Cohort B   Patients with HER2-negative, ER-positive and/or PgR-positive tumours receiving oral dose of Afatinib 50 mg qd